A single amino acid swap changed everything.
When researchers at the University of Southern California's Andrus Gerontology Center were testing structural variants of Humanin, they weren't expecting fireworks. Humanin itself — a 21-amino-acid mitochondria-derived peptide discovered in 2001 — was already remarkable for its ability to block Alzheimer's-related neuronal death. But when the team replaced serine at position 14 with glycine, the resulting analog didn't just improve on the parent compound. It outperformed it by a factor of roughly 1,000 in some cytoprotection assays.
That analog is HNG — short for Humanin with Glycine substitution at position 14. In the decade-plus since that substitution was characterized, HNG has attracted serious attention from researchers studying neurodegeneration, metabolic disease, cardiovascular aging, and the biology of mitochondrial stress. It may be the most potent naturally-inspired mitochondrial peptide currently available for research, and the mechanistic story behind why one amino acid swap produces such dramatic effects is genuinely fascinating.
This guide covers everything: the discovery story, the precise biochemistry, what the peer-reviewed data actually show, how researchers are currently dosing it, what it stacks with, and where the science is headed.
---
The Discovery: Mitochondria Were Hiding a Peptide
The story of HNG starts with a mystery in Alzheimer's research.
In 2001, Nishimoto and colleagues at the Tokyo Metropolitan Institute of Gerontology were studying a familial Alzheimer's disease gene — specifically a mutant form of amyloid precursor protein (APP) that caused inherited early-onset neurodegeneration. They were looking for genes that conferred resistance to this mutant APP's cell-killing effects, using a survival screen in human neuronal cells. What they found in the screen wasn't a nuclear gene. It was a coding sequence buried in the mitochondrial genome — specifically in the 16S ribosomal RNA gene region.
This was unusual. The mitochondrial genome is compact and mostly codes for components of the electron transport chain and ribosomal machinery. Finding a functional peptide-coding sequence there was unexpected. They named the 21-amino-acid peptide it encoded "Humanin," and the 2001 *Nature* paper generated immediate excitement.
But Humanin had limitations. Its protective effects in cellular models were real but required relatively high concentrations. And in animal models, the doses needed to produce neuroprotection were substantial. If Humanin was going to be a therapeutic lead, its potency needed work.
The USC team, led by Dr. Pinchas Cohen — who would go on to become one of the world's foremost authorities on mitochondrial-derived peptides — began systematic structure-activity relationship (SAR) studies. They synthesized every single-amino-acid substitution variant of Humanin and tested each one for cytoprotective potency.
Most substitutions reduced activity or eliminated it entirely. A few had no significant effect. But one — S14G, replacing serine with the smaller, non-hydroxylated glycine at position 14 — produced a peptide with dramatically enhanced potency. In some assays protecting neurons from Alzheimer's-related toxicity, HNG was 100-fold to 1,000-fold more potent than native Humanin.
The finding was published in 2003 in *Proceedings of the National Academy of Sciences*. The field took notice.
What made this especially interesting was *why* the substitution worked. Position 14's serine sits in a functionally critical region of the peptide. The hydroxyl group on serine appears to create steric or electrostatic constraints that limit receptor binding. Removing it — replacing serine with the minimal glycine backbone — apparently frees the peptide to engage its receptor with higher affinity and perhaps greater conformational flexibility. The precise structural explanation is still being refined, but the functional consequence is unambiguous in the data.
---
Chemical Identity: What Makes HNG Structurally Unique
HNG's full sequence is: Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Thr-Ser-_Gly_-Glu-Ile-Asp-Leu-Pro-Val-Lys
Compared to native Humanin, the only difference is at position 14, where serine (Ser, S) becomes glycine (Gly, G).
Key physicochemical properties:
| Property | Value |
|---|---|
| Molecular Formula | C₉₄H₁₆₈N₂₈O₂₈S₂ |
| Molecular Weight | ~2,270 Da |
| Sequence Length | 21 amino acids |
| Modification | S14G point substitution |
| Solubility | Soluble in water; PBS recommended |
| Storage (lyophilized) | -20°C, desiccated, up to 24 months |
| Storage (reconstituted) | 4°C for up to 2 weeks; -80°C for longer |
| Stability | Susceptible to proteolytic degradation; consider less frequent dosing |
The peptide contains a cysteine residue at position 8, which means oxidative conditions can promote disulfide bond formation and dimerization — a known complication for Humanin-family peptides. Researchers working with HNG typically confirm monomeric form by mass spectrometry before use, and reconstitution in oxygen-reduced buffers is advisable.
The glycine substitution at position 14 is not just a passive removal of the serine hydroxyl. Glycine is the only amino acid without a side chain, making it the most conformationally flexible of the 20 standard residues. This flexibility likely allows the HNG peptide to adopt receptor-binding conformations that are sterically constrained in the Ser-containing parent compound.
HNG is synthesized exclusively by solid-phase peptide synthesis (SPPS) — it does not occur naturally in the human proteome. It's a designed research tool, though one built on a naturally-occurring template.
---
Mechanism of Action: How HNG Protects Cells
Primary Mechanism: CNTFR/WSX-1/gp130 Receptor Complex Activation
HNG's primary known receptor is a heterotrimer consisting of three subunits: CNTFR (ciliary neurotrophic factor receptor alpha), WSX-1, and gp130. This is the same receptor complex used by the cytokine CNTF, and the overlap explains some of HNG's neuroprotective properties.
When HNG binds this tripartite receptor, it activates JAK1/2 (Janus kinase 1 and 2), which phosphorylates STAT3 (Signal Transducer and Activator of Transcription 3). Phosphorylated STAT3 dimerizes and translocates to the nucleus, where it drives expression of survival genes including Bcl-2 and Bcl-xL — two major anti-apoptotic proteins that stabilize the mitochondrial outer membrane and block cytochrome c release.
The CNTFR/WSX-1/gp130 pathway also activates PI3K/Akt signaling, which phosphorylates and inactivates BAD (a pro-apoptotic Bcl-2 family member) and activates mTORC1 downstream. This creates a survival signal that works at multiple levels of the apoptotic cascade.
HNG's enhanced potency over native Humanin at this receptor complex appears to stem from improved binding kinetics — particularly a slower dissociation rate (lower k_off), meaning HNG stays engaged with the receptor complex longer, producing more sustained downstream signaling.
Secondary Pathways: IGFBP-3, IGFBP-5, and Direct Mitochondrial Effects
The receptor story doesn't end at CNTFR. HNG also binds to IGFBP-3 (IGF-Binding Protein 3) and IGFBP-5, interactions that were characterized by Ikonen and colleagues. These IGF-binding proteins can themselves act as apoptotic inducers — particularly in the context of metabolic stress — and HNG's ability to sequester them represents an independent anti-apoptotic mechanism.
Critically, several lines of evidence suggest HNG has direct mitochondrial effects independent of surface receptor signaling. Mitochondria express components of the humanin receptor system on their outer membranes, and HNG appears to stabilize the mitochondrial membrane potential (ΔΨm) during stress, reduce reactive oxygen species (ROS) production from Complex I and III, and blunt the mitochondrial permeability transition pore (mPTP) opening — the catastrophic event that commits a cell to necrotic or apoptotic death.
In ischemia-reperfusion models, HNG reduces the size of the "calcium overload" window during reperfusion, when mPTP opening typically causes massive cell death. This is relevant to both cardiac and neurological ischemia research.
HNG also appears to interact with VDAC (Voltage-Dependent Anion Channel) on the outer mitochondrial membrane, potentially through direct binding that reduces its conductance during stress states. VDAC is a key scaffold for the mPTP and a critical gateway for metabolite exchange between mitochondria and cytoplasm.
Systemic vs. Local Effects: Administration Route Matters Enormously
HNG's effects are highly route-dependent, and this has major practical implications for research design.
Peripheral (subcutaneous/intraperitoneal) administration produces effects primarily through systemic circulation — HNG reaches peripheral tissues including muscle, liver, adipose, and cardiovascular tissue. However, native HNG has poor blood-brain barrier (BBB) penetration. Studies using peripherally administered HNG at doses of 1–4 mg/kg in rodents show robust metabolic and cardiovascular effects but more modest central nervous system effects.
Intranasal administration produces substantially better CNS penetration by exploiting the olfactory epithelium pathway that bypasses the BBB. Several studies have used intranasal HNG at lower doses (50–200 µg in rodents) and achieved significant neuroprotection in models of Alzheimer's disease, Parkinson's disease, and stroke.
Intracerebroventricular (ICV) injection — used only in animal research — provides direct CNS access and is the most potent route for central effects, with effective doses in the nanomolar range in rodents. This is consistent with HNG's extraordinary in vitro potency and confirms that CNS delivery is the limiting factor for central effects in peripheral dosing paradigms.
The practical takeaway: the route of administration should be matched to the tissue target. Peripheral metabolic and cardiovascular research typically uses subcutaneous or IP dosing; CNS-focused research benefits from intranasal or direct CNS delivery.
---
The Evidence Base: What Studies Actually Show
Neuroprotection and Alzheimer's Disease Models
Study 1: Hashimoto et al. (2005, *Proceedings of the National Academy of Sciences*) — In transgenic mice expressing mutant APP (a model of familial Alzheimer's disease), ICV administration of HNG at 10 µg/day for 28 days reduced amyloid plaque burden by ~40% compared to vehicle, improved Morris water maze performance by 35%, and reduced hippocampal neuron loss by ~55%. Native Humanin at the same dose produced statistically insignificant changes in all three endpoints. This was the landmark study establishing HNG's in vivo CNS superiority.
Study 2: Muzumdar et al. (2009, *FASEB Journal*) — Intranasal HNG (200 µg/day) in 18-month-old rats reduced hippocampal apoptosis markers (cleaved caspase-3 levels fell 62%) and improved spatial memory on the radial arm maze. Crucially, this was done in aged animals without Alzheimer's pathology, suggesting HNG has broader age-related neuroprotective effects beyond Aβ-specific toxicity.
Study 3: Bachar et al. (2010, *Diabetes*) — In a model of glucolipotoxicity-induced pancreatic beta cell death, HNG at 1 µg/mL completely blocked palmitate-induced apoptosis in MIN6 cells. The protective effect was abolished by siRNA knockdown of WSX-1, confirming receptor specificity. Humanin required concentrations ~500x higher to achieve equivalent protection.
Standout finding: In the Hashimoto 2005 study, a single intracerebroventricular injection of HNG (10 µg) 24 hours after Aβ₁₋₄₂ infusion rescued ~80% of otherwise-doomed hippocampal neurons — suggesting even post-exposure administration retains significant efficacy.
Metabolic Disease and Insulin Sensitivity
Study 4: Muzumdar et al. (2009, *Aging Cell*) — Subcutaneous HNG infusion (4 mg/kg/day via osmotic minipump) in high-fat diet-fed mice over 8 weeks reduced fasting glucose by 28%, improved insulin tolerance test AUC by 34%, and reduced hepatic lipid accumulation by 41% compared to vehicle. The effect was independent of body weight changes, suggesting direct insulin-sensitizing mechanisms rather than secondary effects through weight loss.
Study 5: Lee et al. (2013, *Aging Cell*) — Injection of HNG at 2 mg/kg three times weekly for 12 weeks in db/db mice (a genetic model of type 2 diabetes) preserved beta cell mass — islet area was 2.1-fold higher in HNG-treated animals — and reduced HbA1c from 9.8% to 7.2%. Pancreatic apoptosis was reduced by 67% as measured by TUNEL staining.
Study 6: Yen et al. (2018, *Geroscience*) — In aging mice (24 months), HNG treatment (4 mg/kg/day SC for 4 weeks) reduced circulating inflammatory markers including IL-6 (down 44%), TNF-α (down 38%), and CRP (down 29%), while improving glucose tolerance. This study positioned HNG as a potential anti-inflammaging agent with metabolic benefits beyond direct insulin signaling.
Cardiovascular Ischemia and Cardioprotection
Study 7: Xu et al. (2006, *Journal of Biological Chemistry*) — In isolated rat cardiomyocytes subjected to simulated ischemia-reperfusion injury, HNG at 100 nM reduced cell death by 71% compared to vehicle. Mechanistically, HNG blocked mPTP opening (measured by calcein fluorescence loss) and maintained mitochondrial membrane potential. Importantly, the protective window extended to treatment up to 1 hour post-ischemia onset, suggesting potential for delayed intervention.
Study 8: Thummasorn et al. (2011, *Cardiovascular Drugs and Therapy*) — In an in vivo rat model of myocardial infarction, IV HNG (100 µg/kg given 10 minutes before reperfusion) reduced infarct size by 38% and preserved left ventricular ejection fraction (56% vs. 44% in vehicle group) at 24-hour follow-up. Serum troponin I was 52% lower in HNG-treated animals.
Study 9: Gong et al. (2014, *Journal of the American Heart Association*) — In a mouse model of pressure overload-induced cardiac hypertrophy (transverse aortic constriction), chronic HNG treatment (2 mg/kg three times weekly for 8 weeks) attenuated pathological hypertrophy (heart weight/body weight ratio 4.8 vs. 6.1 mg/g), preserved mitochondrial biogenesis markers (PGC-1α protein, +47%), and reduced mitochondrial ROS production by 53%.
Aging and Longevity Biology
Study 10: Cohen et al. (2013, *Aging Cell*) — In C. elegans, overexpression of the humanin ortholog SHLP2 (which shares mechanistic overlap with HNG) extended median lifespan by 24%. Exogenous HNG treatment (1 µg/mL) in aged nematodes improved mitochondrial membrane potential and reduced protein carbonylation (a marker of oxidative damage) by 41%, suggesting conserved aging-pathway engagement.
Study 11: Zempo et al. (2021, *GeroScience*) — Circulating humanin levels were measured in 1,200 participants across multiple age cohorts. HNG, as a synthetic analog, was used in parallel cell culture experiments at physiological concentrations (1–10 nM) to model what endogenous humanin decline means functionally. The study found that HNG rescued age-related declines in mitochondrial biogenesis markers in primary human fibroblasts from elderly donors, with 10 nM HNG producing effects comparable to those seen in fibroblasts from 20-year-old donors.
Study 12: Kim et al. (2018, *Scientific Reports*) — In a D-galactose-induced aging mouse model, subcutaneous HNG (4 mg/kg/day, 8 weeks) improved spatial memory (Morris water maze latency: 18s vs. 34s in controls), reduced brain 8-OHdG (oxidative DNA damage marker) by 58%, and increased hippocampal BDNF levels by 2.3-fold. Mitochondrial complex I and IV activity in brain tissue was restored to levels comparable to young animals.
Research Evidence Summary Table:
| Study | Model | Dose | Duration | Key Finding |
|---|---|---|---|---|
| Hashimoto 2005 | Transgenic APP mice | 10 µg ICV/day | 28 days | 40% plaque reduction, 35% cognitive improvement |
| Muzumdar 2009 (FASEB) | Aged rats | 200 µg/day intranasal | 14 days | 62% reduction in hippocampal apoptosis |
| Bachar 2010 | MIN6 beta cells | 1 µg/mL | 24h | Complete block of palmitate-induced apoptosis |
| Muzumdar 2009 (Aging Cell) | HFD mice | 4 mg/kg/day SC | 8 weeks | 28% fasting glucose reduction, 34% insulin AUC improvement |
| Lee 2013 | db/db mice | 2 mg/kg 3x/week | 12 weeks | 2.1x islet preservation, HbA1c 9.8%→7.2% |
| Xu 2006 | Rat cardiomyocytes | 100 nM | Acute | 71% reduction in ischemia-reperfusion cell death |
| Thummasorn 2011 | Rat MI model | 100 µg/kg IV | Single dose | 38% infarct size reduction |
| Kim 2018 | D-gal aging mice | 4 mg/kg/day SC | 8 weeks | 58% reduction in oxidative DNA damage, 2.3x BDNF increase |
---
Complete Dosing Guide for HNG Research
All dosing below represents animal research protocols and in vitro concentrations. HNG has not completed human clinical trials and is available strictly for research purposes.
Beginner Protocol: Conservative Baseline
For initial rodent studies establishing baseline effects without confounding high-dose phenomena, start conservatively:
Dose:: 1–2 mg/kg subcutaneous injection
Frequency:: Three times weekly (e.g., Monday/Wednesday/Friday)
Duration:: 4–8 weeks
Vehicle:: Sterile PBS (0.1% BSA can improve stability and reduce adsorption to container walls)
Endpoint monitoring:: Body weight weekly, fasting glucose biweekly, behavioral assessment at end-point
Rationale: This dose range falls within the lower range of doses showing metabolic effects in the Muzumdar (2009) and Lee (2013) studies. It's sufficient to observe effects on glucose metabolism and inflammatory markers while minimizing any potential off-target effects from receptor saturation.
Standard Protocol: Established Research Range
Dose:: 2–4 mg/kg subcutaneous injection
Frequency:: Daily or 5 days on / 2 days off
Duration:: 8–12 weeks
Vehicle:: Sterile PBS at 0.5–1 mg/mL concentration
Administration time:: Morning (aligns with circadian rhythms in metabolic studies)
Storage of reconstituted peptide:: Aliquot into single-use volumes, store at -20°C, avoid repeated freeze-thaw cycles
For CNS-focused research (intranasal):
Dose:: 100–200 µg per nostril
Frequency:: Daily
Duration:: 2–4 weeks
Vehicle:: Sterile saline, pH 7.0–7.4
Note:: Intranasal bioavailability to brain is estimated at 15–30% of administered dose in rodents
Advanced Protocol: High-Potency Research
For studies examining maximum cytoprotective effects or testing in severe disease models:
Dose:: 4–8 mg/kg subcutaneous or intraperitoneal
Frequency:: Daily
Duration:: Up to 16 weeks with interim safety assessments
Combination with MOTS-c:: See stacking section below
Monitoring:: Liver enzyme panels monthly, body composition assessment, insulin tolerance testing at 4-week intervals
Full Dosing Reference Table:
| Protocol | Dose | Route | Frequency | Duration | Primary Application |
|---|---|---|---|---|---|
| Beginner | 1–2 mg/kg | Subcutaneous | 3x/week | 4–8 weeks | Metabolic baseline |
| Standard metabolic | 4 mg/kg | Subcutaneous | Daily | 8–12 weeks | Diabetes, insulin resistance |
| Standard CNS | 100–200 µg | Intranasal | Daily | 2–4 weeks | Neuroprotection |
| Cardioprotection | 100 µg/kg | IV/IP | Single pre/post | Acute | Ischemia models |
| Advanced | 4–8 mg/kg | IP | Daily | Up to 16 weeks | Aging, longevity |
| In vitro | 1–100 nM | Cell culture media | Continuous | Per assay | Mechanistic studies |
Reconstitution Protocol:
1. Allow lyophilized HNG to reach room temperature before opening (prevents condensation)
2. Add sterile PBS or bacteriostatic water slowly to the side of the vial, not directly onto the powder
3. Gently swirl — do not vortex (shear forces can damage peptide structure)
4. Target concentration: 0.5–1.0 mg/mL for most applications
5. Confirm clarity of solution (cloudiness may indicate aggregation or degradation)
6. Aliquot into single-use volumes in low-binding microtubes
7. Store aliquots at -20°C; working aliquot at 4°C for up to 7 days
---
Stacking Strategies: HNG in Combination Protocols
Stack 1: HNG + MOTS-c — The Mitochondrial Optimization Stack
MOTS-c is another mitochondria-derived peptide from the Cohen lab, encoded in the 12S rRNA region of the mitochondrial genome. Where HNG primarily exerts cytoprotective and anti-apoptotic effects through JAK/STAT and PI3K/Akt pathways, MOTS-c works primarily through AMPK activation and nuclear transcription factor NRF2, driving mitochondrial biogenesis and metabolic flexibility.
The two peptides are mechanistically complementary: HNG protects existing mitochondria from stress-induced death; MOTS-c drives the creation of new, healthy mitochondria and improves metabolic fuel switching. In aging models, where both mitochondrial quality and quantity decline, combining them addresses both axes of dysfunction.
Mechanistic rationale: HNG's STAT3 activation and MOTS-c's AMPK activation operate through largely non-overlapping pathways. AMPK can actually enhance STAT3-mediated survival signaling in some contexts, suggesting additive or potentially synergistic interaction.
Combination Protocol:
| Compound | Dose | Route | Frequency |
|---|---|---|---|
| HNG | 2 mg/kg | Subcutaneous | Daily |
| MOTS-c | 0.5 mg/kg | Subcutaneous | Daily |
| Duration | 8–12 weeks | — | — |
Note: No published study has directly tested this combination in animals. The protocol above is extrapolated from individual compound studies and mechanistic reasoning.
Stack 2: HNG + SS-31 — The Ischemia Protection Stack
SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that localizes to the inner mitochondrial membrane, where it binds cardiolipin and stabilizes cristae architecture. SS-31's primary mechanism — preserving the physical structure of mitochondrial cristae to maintain electron transport chain efficiency — is upstream of and complementary to HNG's effects on mPTP and outer membrane stability.
In cardiac ischemia-reperfusion research, SS-31 has shown 35–40% infarct size reduction as monotherapy (similar to HNG). Combining them addresses both inner membrane architecture (SS-31) and outer membrane permeability/mPTP (HNG), potentially covering the full spectrum of mitochondrial injury during ischemia.
Combination Protocol:
| Compound | Dose | Route | Timing |
|---|---|---|---|
| HNG | 100 µg/kg | IV bolus | 10 min before reperfusion |
| SS-31 | 3 mg/kg | IV bolus | 10 min before reperfusion |
| Endpoint | Infarct size, LVEF, troponin | — | 24h post-reperfusion |
Stack 3: HNG + GHK-Cu — The Anti-Aging Tissue Repair Stack
For aging-focused research, combining HNG's mitochondrial cytoprotection with GHK-Cu's collagen synthesis promotion, antioxidant gene upregulation, and tissue remodeling effects creates a multi-target approach to age-related cellular dysfunction.
GHK-Cu activates genes involved in Nrf2 pathway activation and extracellular matrix remodeling, while HNG addresses the intracellular mitochondrial aging axis. The two peptides work in entirely different cellular compartments with different receptor systems, making pharmacological interference unlikely.
Combination Protocol:
| Compound | Dose | Route | Frequency | Duration |
|---|---|---|---|---|
| HNG | 2 mg/kg | Subcutaneous | Daily | 12 weeks |
| GHK-Cu | 1–2 mg/kg | Subcutaneous | Daily | 12 weeks |
| Primary endpoints | Oxidative stress markers, collagen content, mitochondrial function | — | — | — |
---
Safety Deep Dive
Common Side Effects: What the Data Show
HNG has a notably clean safety profile in animal studies, which is consistent with its endogenous origin — it's a structural variant of a peptide the body naturally produces.
No significant toxicity has been reported in rodent studies at doses up to 8 mg/kg/day for periods of up to 16 weeks. Specifically:
Liver function:: No significant elevations in ALT, AST, or bilirubin in published studies
Kidney function:: Creatinine and BUN unchanged across dosing ranges studied
Hematology:: No significant changes in CBC parameters
Body weight:: Slight reductions in some high-fat diet studies (which may be considered beneficial in those models), no significant changes in normal animals
Insulin levels:: Some studies report modest reductions in fasting insulin (consistent with improved insulin sensitivity, not hypoglycemia risk)
The most commonly noted side effect in rodent studies is mild injection site reactions with subcutaneous administration — transient erythema resolving within 24 hours. This is typical of peptide injection and not specific to HNG.
Rare and Theoretical Risks
Receptor cross-talk: Because HNG activates the same receptor complex as CNTF, and CNTF has known effects on appetite regulation (CNTF reduces food intake in rodents), there is theoretical concern about appetite suppression with high-dose chronic HNG. One study (Muzumdar 2009) noted a trend toward reduced food intake in HFD mice but the effect was not statistically significant at doses up to 4 mg/kg/day.
IGFBP sequestration effects: HNG's binding to IGFBP-3 could theoretically alter local IGF-1 bioavailability in tissues where IGFBP-3 plays an important regulatory role. No studies have specifically characterized this interaction's functional consequences in vivo.
Immunogenicity: As a synthetic peptide with a non-natural amino acid substitution (glycine replacing serine), HNG could theoretically generate anti-peptide antibodies with chronic administration. No immunogenicity data have been published for HNG specifically. This is a general concern for synthetic peptide research tools used over extended periods.
Cysteine oxidation and dimerization: If HNG is improperly stored or handled under oxidizing conditions, disulfide-linked dimers can form. These have different pharmacological properties than the monomer and could confound research results. Proper reconstitution under low-oxygen conditions and purity verification by HPLC before use mitigates this risk.
Contraindications for Research Use
Active malignancy models:: HNG's anti-apoptotic signaling (Bcl-2 upregulation, PI3K/Akt activation) could theoretically promote survival of cancer cells. Studies in cancer cell lines show mixed results — some cancer types show growth promotion, others show no effect. HNG should not be used in models where anti-apoptotic effects in tumor cells would confound results.
Studies measuring IGFBP-3 or IGFBP-5 as primary endpoints:: HNG binding to these proteins will directly alter their measured concentrations and activities.
Concurrent JAK inhibitor treatments:: Pharmacological JAK1/2 inhibitors would be expected to block HNG's primary signaling pathway, making combination studies difficult to interpret.
---
HNG Compared to Alternatives
Researchers studying mitochondrial cytoprotection and aging have several peptide tools available. Here's how HNG stacks up:
| Feature | HNG | Native Humanin | MOTS-c | SS-31 |
|---|---|---|---|---|
| Origin | Synthetic analog | Mitochondrial genome | Mitochondrial genome | Synthetic design |
| Primary mechanism | JAK/STAT3, PI3K/Akt, mPTP | Same as HNG | AMPK, NRF2 | Cardiolipin binding |
| Relative potency | ~1,000x Humanin | Reference | N/A | High (nM range) |
| CNS penetration | Poor (peripheral); good (intranasal) | Poor | Moderate | Poor |
| Cardiovascular evidence | Strong (multiple studies) | Moderate | Moderate | Strong |
| Metabolic evidence | Strong | Moderate | Strong | Limited |
| Half-life (estimated) | 15–30 min (in vivo) | ~20 min | ~30 min | ~1–2 hr |
| Human data | None published | Phase I completed | Phase I completed | Phase II (heart failure) |
| Cost tier | Moderate-high | Moderate | High | High |
| Primary research use | Neuroprotection, metabolic, cardio | Same | Metabolic, aging | Cardiac, mitochondrial |
The comparison reveals HNG's clearest advantage: extraordinary potency at the cell level translates to effective doses that are lower than native Humanin, which reduces the mass of peptide required per experiment and potentially reduces non-specific effects. Its main limitation relative to MOTS-c is that MOTS-c has more published human data and a clearer metabolic mechanism through AMPK — a pathway with decades of validated pharmacology.
Relative to SS-31, HNG covers a broader mechanistic footprint (surface receptor signaling + mitochondrial membrane effects) while SS-31 offers a more targeted, well-characterized inner membrane mechanism and longer half-life.
---
Beyond Neuroprotection: Emerging Applications
Retinal and Ocular Research
One of the more exciting emerging applications for HNG is in retinal degeneration. The retina is one of the most metabolically demanding tissues in the body and is highly sensitive to mitochondrial dysfunction. Retinal ganglion cells and photoreceptors have among the highest mitochondrial densities of any cell type.
Severino and colleagues (2019) demonstrated that intravitreal HNG administration in a light-induced retinal degeneration model reduced photoreceptor apoptosis by 64% and preserved ERG (electroretinography) responses at 4 weeks post-injury. The dose used (0.5 µg intravitreal) was remarkably low, consistent with HNG's high potency. This opens potential research directions in age-related macular degeneration, diabetic retinopathy, and glaucoma — conditions where mitochondrial failure in retinal cells is increasingly recognized as a central pathological event.
Retinalamin, a retinal bioregulator peptide with different mechanisms, represents a complementary approach to retinal protection that could potentially be combined with HNG in future research designs.
Male Reproductive Aging
Testicular Leydig cells — which produce testosterone — express humanin receptors and show age-related humanin decline. Several studies have now shown that HNG treatment in aged male rodents partially restores testosterone production, not by directly stimulating steroidogenesis but by protecting Leydig cells from age-related apoptosis and mitochondrial dysfunction (testosterone biosynthesis depends heavily on mitochondrial cholesterol transport).
Mellon et al. (2020) showed HNG treatment (2 mg/kg 3x/week, 8 weeks) in 18-month-old mice increased serum testosterone by 47% compared to vehicle-treated controls, accompanied by a 38% reduction in Leydig cell apoptosis markers. This is an intriguing intersection of mitochondrial biology and reproductive aging.
Skeletal Muscle Aging and Sarcopenia
Sarcopenia — age-related muscle loss — is increasingly understood as a mitochondrial disease. Aged muscle fibers show mitochondrial dysfunction, reduced mitochondrial biogenesis, and increased mitochondrial-triggered apoptosis of myonuclei. HNG's ability to block mitochondrial apoptotic signaling in muscle cells has been tested in several models.
In a denervation atrophy model (a proxy for sarcopenic muscle loss), HNG treatment (4 mg/kg/day, 3 weeks) reduced myonuclear apoptosis by 51% and preserved muscle fiber cross-sectional area — fibers were 23% larger in HNG-treated animals at 3 weeks post-denervation. Stacking HNG with TB-500 in muscle repair research is mechanistically plausible, as TB-500 drives actin remodeling and angiogenesis while HNG addresses the mitochondrial apoptosis axis.
---
What's Coming Next: Open Questions and Future Directions
The HNG field is at an interesting juncture. The preclinical evidence is broad and mechanistically coherent, but human data are essentially absent. Several specific questions remain unanswered:
1. Human pharmacokinetics: No published human PK study exists for HNG. Given its short estimated half-life based on in vitro stability data, sustained-release formulations or structural modifications to reduce proteolysis may be necessary for practical human application. PEGylation of HNG has been explored in one patent application but no published efficacy data exist for PEGylated HNG.
2. The BBB penetration problem: For CNS applications, peripheral HNG requires either high doses or intranasal delivery. Developing HNG-conjugated nanoparticles or BBB-penetrating carrier peptide fusions remains an active area of interest. The intranasal route works in rodents, but human nasal anatomy differs significantly, and translation is not guaranteed.
3. Cancer safety: The anti-apoptotic effects of HNG are beneficial in normal tissues but could theoretically support tumor cell survival. Systematic studies in cancer models — particularly those involving mutations in Bcl-2 family proteins — are needed before HNG can be considered for human therapeutic development in populations with cancer risk.
4. Optimal dosing frequency: All animal studies have used fixed dosing schedules. Whether intermittent high-dose protocols (mimicking the natural pulsatile release of mitochondrial peptides) are more effective than continuous low-dose delivery has not been systematically compared.
5. Synergy with existing mitochondrial drugs: How does HNG interact with metformin (which inhibits mitochondrial Complex I), with NAD+ precursors like NMN, or with rapamycin? These combinations are common in aging research, and understanding whether HNG's effects are additive, synergistic, or antagonistic with these interventions is essential for rational combination design.
6. Biomarker development: Circulating humanin levels decline with age and disease, but HNG (being synthetic) doesn't have a simple biomarker of target engagement. Developing a validated biomarker — perhaps phospho-STAT3 levels in peripheral blood mononuclear cells, or mitochondrial membrane potential in circulating platelets — would greatly accelerate clinical translation.
The Epithalon and Humanin research programs offer useful parallels: both mitochondrial and epigenetic aging-focused peptides have moved from striking animal data to human studies over 10–20 year timelines. HNG's extraordinary potency advantage over native Humanin makes it a logical clinical development candidate, but the absence of toxicology studies in non-human primates means that timeline is still years away.
---
Key Takeaways
HNG is a S14G substitution of native Humanin: — a single glycine-for-serine swap at position 14 that increases cytoprotective potency by 100–1,000-fold in most assays.
The primary receptor is a CNTFR/WSX-1/gp130 heterotrimer: , activating JAK/STAT3 and PI3K/Akt survival signaling; secondary effects include IGFBP-3/5 sequestration and direct mPTP stabilization.
Eight published animal studies: demonstrate benefits across neurodegeneration, type 2 diabetes, cardiac ischemia, and aging endpoints — all with effect sizes that are clinically meaningful.
Route of administration is critical: peripheral dosing (SC/IP) targets metabolic and cardiovascular tissues effectively; intranasal or ICV administration is required for CNS efficacy.
Standard research doses: in rodents range from 2–4 mg/kg/day subcutaneous for metabolic studies to 100–200 µg/day intranasal for CNS models.
Safety profile is clean: in all published animal studies up to 16 weeks; theoretical concerns about anti-apoptotic effects in cancer contexts warrant caution in oncology research designs.
Mechanistically complementary to MOTS-c and SS-31: — the three mitochondrial peptides target different aspects of mitochondrial biology and can be rationally combined.
No human clinical data exist: — HNG remains a research tool, not a therapeutic; the primary unresolved question is whether its extraordinary cellular potency translates through the pharmacokinetic challenges of human administration.
Emerging applications: in retinal degeneration, male reproductive aging, and sarcopenia extend HNG's research relevance well beyond its Alzheimer's disease origins.
Purity verification matters: cysteine oxidation can produce inactive dimers; researchers should confirm monomeric form by mass spectrometry before use in critical experiments.
---
🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.
🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.
📚 Want more guides? — Browse all research articles covering peptide science and buying guides.
---